Prostate cancer is commonly associated with lower urinary tract symptoms (LUTS). The use of GnRH agonists or antagonists (first line ADT) is widely used as the primary treatment for advanced prostate cancer (pc) and/or to reduce prostate volume (TPV). It is thought that the ADT contributes to the development of LUTS. Researchers pooled multiple other [...]
Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events. The six analyses compared data from randomized trials that [...]
Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]
Will the Centers for Medicare & Medicaid Services (CMS) be able to optimize patient care with regard to both on-label and off-label drugs? CMS', at this time, has not shown itself to be either in favor or against new technology or the introduction of new uses for drugs. They still seem interested in promoting access [...]
New data, published September 1 in the Journal of Urology, shows that Firmagon® (degarelix) which is a gonadotropin-releasing hormone therapy (GnRH) given to men with advanced prostate cancer may be superior to leuprolide when used over three years. This new study (CS21A) was an open-label extension of the Phase III study (CS21) in which Firmagon® [...]